Study Summary
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from pediatric and young adult subjects with relapsed/refractory B-cell malignancies (leukemia and lymphoma). Another purpose of this study is to test the safety and cancer killing ability of a cell therapy against a new cancer target (CD22).
Want to learn more about this trial?
Request More InfoInterventions
FludarabineDRUG
Fludarabine is a purine antagonist antimetabolite
CyclophosphamideDRUG
Cyclophosphamide is a nitrogen mustard derivative alkylating agent
Autologous CD22 CAR TDRUG
Autologous T cells transduced with lentiviral vector (m971BBZ) Chimeric Antigen Receptor (CD22 CAR)
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Stanford Medical Center | Stanford | California | United States |